Emerging Company Profile
Cytovia: activating NK cells at the tumor site
Emerging Company Profile: With its R&D center up and running and a manufacturing facility by year-end, Cytovia aims to enter the clinic early 2022
Cytovia is leveraging its two NK cell platforms and at least 11 partnerships to enter the clinic next year with several therapies targeting both solid and liquid tumors.
Jul 30, 2021 | 8:52 PM GMT
After bolstering its management team with new